Comunicati Stampa

Nantes (Francia) - 14 settembre 2009: VIVALIS (NYSE Euronext Paris: VLS), azienda biofarmaceutica che fornisce soluzioni cellulari innovative all industria farmaceutica per la produzione di vaccini e proteine e sviluppa farmaci per la prevenzione e la cura di malattie virali, parteciperà al Midcap Event il 21 e 22 settembre 2009 . Questo forum si terrà presso il Palais Brongniart, al 19 rue Notre-Dame des Victoires, 75002 Parigi, Francia . VIVALIS ha registrato dall inizio dell anno risultati scientifici e commerciali molto solidi, con la firma di 7 nuove licenze che portano a 27 il totale delle licenze firmate per applicazioni sia di vaccini che di proteine . At the same time, VIVALIS remains in a solid financial situation with 24 . 6 million euros in cash and cash equivalent at June 30, 2009 . VIVALIS will be located at the Arkeon Finance stand . During these two days, fund managers will have the opportunity to exchange with Franck Grimaud, CEO, and Philippe Rousseau, CFO on the performance to date as well as its strategy and perspectives . **********************About the EB66® lineThe EB66® cell line, derived from duck embryonic stem cells, presents unique industrial and regulatory characteristics such as long-term genetic stability, immortality and cell growth to high cell densities in suspension in a serum-free medium (>20 millions cells/mL) . The BMF (Biologics Master File) for the registration of the EB66® cell line with the FDA (U . S . Food and Drug Administration) was filed on June 27, 2008 . The EB66® cell line is currently used or being tested by 75% of the major players in vaccines . VIVALIS has furthermore demonstrated that the EB66® cell line can be easily genetically modified, permitting the expression of recombinant proteins of potential interest . Moreover the glycosylation profile of monoclonal antibodies produced through EB66® cell lines is similar to the glycosylation profiles of human monoclonal antibodies with the added benefit of being distinguished by reduced fucose content . This latter characteristic is known to be associated with a higher level of antibody cytotoxic activity, particularly useful in the treatment of cancer cells . . About VIVALIS (www . vivalis . com)VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases . VIVALIS expertise and intellectual property are exploited in three main areas:1 . The development and manufacturing of vaccines . VIVALIS offers research and commercial licenses for its EB66® cell line, derived from duck stem cells, to pharmaceutical and biotechnology companies for the production of vaccines . Vivalis receives upfront fees, milestone payments and royalties on its licensees net sales . 2 . The development of production systems for recombinant proteins and monoclonal antibodies . VIVALIS licenses its EB66® cell line for the production of recombinant proteins to biotechnology and pharmaceutical companies . Vivalis receives upfront fees, milestone payments and royalties on its licensees net sales . 3 . The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (hepatitis C) . Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (1,450 employees), the second largest group worldwide in animal genetic selection . VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, CSL, Kaketsuken, Merial, Intervet, SAFC Biosciences . VIVALIS is a member of the French ATLANTIC BIOTHERAPIES bio-cluster .

VIVALIS
Listed on Euronext Paris - Compartment C of NYSE Euronext
Reuters: VLS . PA - Bloomberg: VLS FP
Included in NYSE Euronext s Next Biotech index

ContactsVIVALISFranck Grimaud, CEOEmail: investors@vivalis . comNewCapFinancial communications agencySteve Grobet / Emmanuel HuynhTel . : +33 (0) 1 44 71 94 91Email: vivalis@newcap . frCopyright Hugin Questo comunicato é distribuito da Hugin . L emittente è l unico responsabile per il contenuto del comunicato . [CN#158276]